ASH: Out With The Old, In With The New As BMS Ushers In CELMoD Class

With the mega-blockbuster immunomodulatory drug (IMiD) class on its way to fully losing patent protection, Bristol Myers Squibb is banking on the cereblon E3 ligase modulatory drug (CELMoD) class to replace it, and the firm has been releasing early data on a pair of myeloma assets from the program nearing the market.

New York-based BMS presented Phase I/II data for the CELMoD candidate mezigdomide looking at ways of combining it with other...